Amanote Research
Register
Sign In
35. Efficacious and Sustained Canavan Gene Therapy by Single rAAV Injections via IV at Postnatal Day 21 or ICV at a 100 Fold Lower Dose
Molecular Therapy
- United States
doi 10.1016/s1525-0016(16)34370-2
Full Text
Open PDF
Abstract
Available in
full text
Categories
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Date
May 1, 2013
Authors
Unknown
Publisher
Elsevier BV
Related search
Suppression of RDS Expression by siRNA and Gene Replacement Strategies for Gene Therapy Using rAAV Vector
Advances in Experimental Medicine and Biology
Biochemistry
Medicine
Genetics
Molecular Biology
Remodeling of Cortical Bone Allografts Mediated by Adherent rAAV-RANKL and VEGF Gene Therapy
Nature Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
Effect of Alternate-Day, Single-Dose, Corticosteroid Therapy on Pituitary-Adrenal Function.
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Retinal Gene Delivery by rAAV and DNA Electroporation
Current Protocols in Microbiology
Medicine
Virology
Parasitology
Microbiology
Effect of Single Dose Intraoperative IV Acetaminophen in Pediatric Tonsillectomy or Adenotonsillectomy
Egyptian Journal of Anaesthesia
Anesthesiology
Pain Medicine
Identification by Random Forest Method of HLA Class I Amino Acid Substitutions Associated With Lower Survival at Day 100 in Unrelated Donor Hematopoietic Cell Transplantation
Bone Marrow Transplantation
Transplantation
Hematology
Surfactant Protein a and D Polymorphisms: Personalized Medicine or a Day at the Sp-A
Journal of Thoracic and Cardiovascular Surgery
Respiratory Medicine
Pulmonary
Cardiovascular Medicine
Surgery
Cardiology
A Complete Response Induced by 21-Day Sorafenib Therapy in a Patient With Advanced Hepatocellular Carcinoma
Internal Medicine
Internal Medicine
Medicine
Rescuing Canavan Disease: Engineering the Wrong Cell at the Right Time
Journal of Inherited Metabolic Disease
Genetics
